Clinical research of maintenance therapy for patients with advanced non-small cell lung cancer

Li ZHANG
DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.09.003
2010-01-01
Abstract:The first-line chemotherapy with platinum-based regimens for 4 to 6 cycles is a standard care in advanced non-small cell lung cancer (NSCLC). However, for patients who got disease stabilization or maximal response after first line chemotherapy, how to choose safe and efficacy anticancer agents to extend first-line treatment and provide a better clinical benefit is deserving of more concerns currently. In this article,the clinical progress of the chemotherapy and molecular targeted agents as maintenance therapy for patients with advanced NSCLC is reviewed.
What problem does this paper attempt to address?